Analyzing Lyell Immunopharma Inc (LYEL)’s financial ratios for investment purposes

As of close of business last night, Lyell Immunopharma Inc’s stock clocked out at $2.66, up 8.57% from its previous closing price of $2.45. In other words, the price has increased by $+0.2100 from its previous closing price. On the day, 881498 shares were traded. LYEL stock price reached its highest trading level at $2.6700 during the session, while it also had its lowest trading level at $2.4500.

Ratios:

To gain a deeper understanding of LYEL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.07 and its Current Ratio is at 16.07. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.09.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on August 28, 2023, Downgraded its rating to Neutral and sets its target price to $5 from $15 previously.

On November 14, 2022, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight and also lowered its target price recommendation from $15 to $7.

Goldman Downgraded its Buy to Neutral on November 11, 2022, whereas the target price for the stock was revised from $13 to $7.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 15 ’23 when Klausner Richard sold 58,020 shares for $2.28 per share. The transaction valued at 132,286 led to the insider holds 930,880 shares of the business.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LYEL now has a Market Capitalization of 622.54M and an Enterprise Value of 139.48M. For the stock, the TTM Price-to-Sale (P/S) ratio is 5199.28 while its Price-to-Book (P/B) ratio in mrq is 1.03. Its current Enterprise Value per Revenue stands at 1.07k whereas that against EBITDA is -0.62.

Stock Price History:

Over the past 52 weeks, LYEL has reached a high of $3.97, while it has fallen to a 52-week low of $1.32. The 50-Day Moving Average of the stock is 2.1934, while the 200-Day Moving Average is calculated to be 2.1331.

Shares Statistics:

It appears that LYEL traded 923.17K shares on average per day over the past three months and 813.57k shares per day over the past ten days. A total of 253.96M shares are outstanding, with a floating share count of 117.74M. Insiders hold about 53.66% of the company’s shares, while institutions hold 27.92% stake in the company. Shares short for LYEL as of Mar 28, 2024 were 18.1M with a Short Ratio of 19.61, compared to 10.95M on Feb 29, 2024. Therefore, it implies a Short% of Shares Outstanding of 7.12% and a Short% of Float of 10.15%.

Earnings Estimates

As of right now, 3 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.21 for the current quarter, with a high estimate of -$0.18 and a low estimate of -$0.24, while EPS last year was -$0.27. The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.18 and low estimates of -$0.25.

Analysts are recommending an EPS of between -$0.74 and -$0.97 for the fiscal current year, implying an average EPS of -$0.85. EPS for the following year is -$0.89, with 3 analysts recommending between -$0.81 and -$1.02.

Most Popular

[the_ad id="945"]